Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Medicine, Hematology, Oncology +14

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

B. Coiffier, Corinne Haïoun, Nicolas Ketterer et al. · PubMed · 1998 · 898 citations

Life Sciences, Immunology, Oncology +15

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

Roberto Stasi, Adalberto Pagano, Elisa Stipa et al. · Blood · 2001 · 549 citations · Full text

Life Sciences, Hematology, Immunology +12

Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity

John C. Byrd, Timothy J. Murphy, Robin Howard et al. · Journal of Clinical Oncology · 2001 · 511 citations

Pharmacy, Oncology, Pharmacokinetics +15